Le Lézard
Classified in: Health
Subject: AWD

Harrington Discovery Institute at University Hospitals announces 2019 grant funding to 10 physician-scientists


CLEVELAND, Dec. 10, 2018 /PRNewswire/ -- The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2019 Harrington Scholar-Innovator Award recipients. The projects supported by the awards include new therapeutics to treat metabolic disorders, autoimmune disorders and cancer, and new approaches to eradicate parasitic diseases in developing countries.

The Harrington Discovery Institute?part of The Harrington Project for Discovery & Development?is designed to translate science of great promise into therapeutics that can impact human health. Award recipients whose research demonstrates innovation, creativity and the potential to impact standards of care in medicine are selected from institutions across the U.S.  In addition to financial support, the Harrington Discovery Institute provides expertise and oversight in all aspects of drug development.

"Every year we see novel and creative approaches for treating major unmet medical needs. This year was no exception. The 2019 Scholar-Innovator class represents an exciting portfolio of drugs-in-the-making with potential to significantly improve human health. We are honored to support these extraordinary physician-scientists," Jonathan S. Stamler, MD, President of the Harrington Discovery Institute.

The selected scholars have access to several rounds of capital (up to a total of $700,000) through their affiliation with the Harrington Discovery Institute to support the transition of their work into the private sector. Scholars are then free to approach investors of their choice to support the commercialization of their work. They also have facilitated access to BioMotiv, the mission-aligned development company that is part of The Harrington Project.

"Our new class of scholars was selected from a large pool of highly qualified individuals from across the U.S. With this year's class, we have supported over 100 Harrington Scholars," said Mukesh K. Jain, MD, Chief Scientific Officer of the Harrington Discovery Institute.

The 2019 Harrington Scholar-Innovator Award recipients are:

Robert Anderson, MD, PhD ? University of Oklahoma Health Sciences Center
Treating systemic diseases with very long fatty acids

Rosa Bacchetta, MD ? Stanford University
Genetically modified T cells to treat autoimmune disorders

Gerald Dorn, MD ? Washington University School of Medicine
Targeting mitochondria to treat Charcot Marie Tooth and other neurodegenerative disorders

Joachim Herz, MD ? University of Texas Southwestern
Targeting chronic inflammatory diseases

Paul Hruz, MD, PhD ? Washington University School of Medicine
Novel treatment of non-alcoholic fatty liver disease

Peng Ji, MD, PhD ? Northwestern University Feinberg School of Medicine
Identification of new therapeutics for blood cancers

V. Vinod Mootha, MD ? University of Texas Southwestern
Precision medicine for age-associated vision loss

Dawn Wetzel, MD, PhD ? University of Texas Southwestern
Developing novel, broad-based antiparasitics

T.C. Wu, MD, PhD ? The Johns Hopkins School of Medicine
Augmenting universal immunity to combat cancer

Ellen Yeh, MD, PhD ? Stanford University
Novel therapeutics to treat malaria

Harrington Discovery Institute
The Harrington Discovery Institute at University Hospitals in Cleveland, OH?part of The Harrington Project for Discovery & Development?aims to advance medicine and society by enabling our nation's most inventive scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a 'Better World'.

The Harrington Project for Discovery & Development
The Harrington Project for Discovery & Development (The Harrington Project), founded in 2012 by the Harrington Family and University Hospitals of Cleveland, is a $300 million national initiative built to bridge the translational valley of death. It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery into pharma pipelines.

For more information about The Harrington Project and the Harrington Discovery Institute, visit: HarringtonDiscovery.org.

University Hospitals
For information, please go to UHhospitals.org.

 

SOURCE University Hospitals, Cleveland


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: